Company news
Patrys Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Appendix 4D - Half Year Accounts - 31 December 2020
February 19, 2021
Patrys Successfully Establishes PAT-DX1 Stable Cell Line
February 9, 2021
Appendix 4C - Quarterly - 31 December 2020
January 27, 2021
$7.3M Capital Raising
November 8, 2020
Investor Presentation - November 2020 - Updated
November 5, 2020
Investor Presentation - November 2020
November 4, 2020
Appendix 4C - Quarterly - 30 September 2020
October 25, 2020
First patent granted for Deoxymab-nanoparticles
October 5, 2020
Patrys Adds Full Human Antibody to Deoxymab Portfolio
September 28, 2020
Patrys adds full human antibody to Deoxymab portfolio
September 27, 2020
Appendix 4E and 2020 Annual Report
August 24, 2020
Entitlement Offer Results and Shortfall Notification
August 3, 2020
Appendix 4C - Quarterly - 30 June 2020
July 30, 2020
$4.29 Million Fully Underwritten Rights Issue
June 22, 2020
Investor Presentation - June 2020
June 17, 2020
Appendix 4C - Quarterly - 31 March 2020
April 26, 2020
PAT-DX1 mechanism for crossing blood brain barrier confirmed
March 15, 2020
PAT-DX1-NP crosses BBB and targets tumours
March 1, 2020
Appendix 4D - Half Year Accounts - 31 December 2019
February 24, 2020
Appendix 4C - Quarterly - 31 December 2019
January 29, 2020
Appendix 4C - Quarterly - 30 September 2019
October 28, 2019
Appendix 4E and 2019 Annual Report
August 22, 2019
Appendix 4C - Quarterly - 30 June 2019
July 29, 2019
PAT-DX1 significantly improves survival in aggressive GBM
July 21, 2019
Europe grants patent for Deoxymab 3E10
July 17, 2019
PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy
May 29, 2019
Appendix 4C - Quarterly - 31 March 2019
April 23, 2019
Market Update
March 29, 2019
Appendix 4D - Half Year Accounts - 31 December 2018
February 20, 2019
Appendix 4C - Quarterly - 31 December 2018
January 30, 2019
PAT-DX1 Suppresses Breast Cancer Brain Metastases
December 19, 2018
Appendix 4C - Quarterly - 30 September 2018
October 30, 2018
Settlement of Manufacturing Claims
October 24, 2018
PAT-DX1 Clinical Target Indications Confirmed
October 4, 2018
Patrys and WEHI Awarded Grant
August 28, 2018
Appendix 4E and 2018 Annual Report
August 24, 2018
Patent Granted for Pre-clinical IgM Candidate PAT-LM1
August 1, 2018
Appendix 4C - Quarterly - 30 June 2018
July 25, 2018
Preliminary PAT-DX1 pharmacokinetics
July 5, 2018
China and Japan both grant patents for Deoxymab 3E10
July 3, 2018
PAT-DX1 Targets and Kills Brain Cancer Stem Cells
May 30, 2018
Patrys Increases Capital Raising to $4.6 million
May 20, 2018
New Pre-Clinical Collaboration on PAT-DX1
May 16, 2018
Patrys Completes $3.5M Placement
May 15, 2018
Appendix 4C - Quarterly - 31 March 2018
April 26, 2018
PAT-DX1 Improves Survival in Animal Model of Glioblastoma
March 18, 2018
PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size
February 27, 2018
Appendix 4D - Half Year Accounts - 31 December 2017
February 23, 2018
Appendix 4C - Quarterly - 31 December 2017
January 31, 2018
Publication and Patent Filing for Humanized Version of 3E10
January 30, 2018
Decks
The 5 newest of 43 decks. Every deck is listed under its year.
- Investor Presentation (October 2026)
Investor deck · 17 slides · Oct 13, 2026
- Investor Presentation (July 2026)
Investor deck · 19 slides · Jul 27, 2026
- Investor Presentation (March 2026)
Investor deck · 14 slides · Mar 31, 2026
- Investor Presentation (January 2026)
Investor deck · 21 slides · Jan 28, 2026
- Shareholder Meeting (November 2024)
Shareholder meeting · 18 slides · Nov 22, 2024